Medicure Inc. (MPH.V)
- Previous Close
1.0000 - Open
1.0000 - Bid 1.0000 x --
- Ask 1.0600 x --
- Day's Range
1.0000 - 1.0000 - 52 Week Range
0.6300 - 1.2600 - Volume
4,286 - Avg. Volume
1,931 - Market Cap (intraday)
10.436M - Beta (5Y Monthly) 0.69
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1000 - Earnings Date May 26, 2025 - May 30, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL, to treat neurological indications, such as Tardive Dyskinesia. It offers products through retail and mail order pharmacies. The company was founded in 1997 and is headquartered in Winnipeg, Canada.
www.medicure.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: MPH.V
View MorePerformance Overview: MPH.V
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MPH.V
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MPH.V
View MoreValuation Measures
Market Cap
10.44M
Enterprise Value
4.12M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.48
Price/Book (mrq)
0.50
Enterprise Value/Revenue
0.19
Enterprise Value/EBITDA
2.67
Financial Highlights
Profitability and Income Statement
Profit Margin
-4.74%
Return on Assets (ttm)
-5.93%
Return on Equity (ttm)
-5.11%
Revenue (ttm)
21.91M
Net Income Avi to Common (ttm)
-1.04M
Diluted EPS (ttm)
-0.1000
Balance Sheet and Cash Flow
Total Cash (mrq)
7.19M
Total Debt/Equity (mrq)
4.21%
Levered Free Cash Flow (ttm)
573.75k